Ford Motor Company vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Ford Motor Company trades at $12.16 (market cap $48.85B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.64 (market cap $2.27B). The key difference: Ford Motor Company is far larger — about 21.5× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Ford Motor Company pays a 4.9% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| F | SLS | |
|---|---|---|
Market Cap | $48.85B | $2.27B |
Volume | 57,748,965 | 4,179,659 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $15.46 |
52-Week Low | $11.21 | $1.39 |
Typical Hold Time | 105 Days | — |
Enterprise Value | $180.81B | $2.14B |
Dividend Yield | 4.9% | — |
Signals from Pluang's Aura AI — not financial advice
Ford Motor Company (F) trades at $12.23, up 0.87% with a mixed technical picture showing bearish moving averages but neutral oscillators. Fundamentally, the company reported a net loss of $8.18 billion in 2025 despite $187.27 billion revenue, with negative profit margins and high debt levels. Recent news highlights a 6.6% Q3 sales decline and supplier disruptions affecting F-150 production, though the company maintains its No. 3 U.S. sales position.
The outlook remains challenging with persistent losses and competitive pressures, though analyst consensus suggests 30% upside to the $15.90 price target. Key risks include ongoing operational issues, high leverage, and market share erosion to Asian rivals. Investment appeal hinges on execution improvements and hybrid vehicle transition success.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →